Cognition Therapeutics Statistics
Total Valuation
CGTX has a market cap or net worth of $20.26 million. The enterprise value is $4.30 million.
Important Dates
The last earnings date was Wednesday, May 7, 2025, before market open.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CGTX has 61.97 million shares outstanding. The number of shares has increased by 49.90% in one year.
| Current Share Class | 61.97M |
| Shares Outstanding | 61.97M |
| Shares Change (YoY) | +49.90% |
| Shares Change (QoQ) | +38.38% |
| Owned by Insiders (%) | 0.54% |
| Owned by Institutions (%) | 8.60% |
| Float | 55.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.65 |
| P/TBV Ratio | 1.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.09, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.09 |
| Quick Ratio | 1.94 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,681.95 |
Financial Efficiency
Return on equity (ROE) is -161.93% and return on invested capital (ROIC) is -157.25%.
| Return on Equity (ROE) | -161.93% |
| Return on Assets (ROA) | -107.53% |
| Return on Invested Capital (ROIC) | -157.25% |
| Return on Capital Employed (ROCE) | -427.40% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.19M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.15% in the last 52 weeks. The beta is 0.99, so CGTX's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | -83.15% |
| 50-Day Moving Average | 0.40 |
| 200-Day Moving Average | 0.56 |
| Relative Strength Index (RSI) | 37.74 |
| Average Volume (20 Days) | 915,137 |
Short Selling Information
The latest short interest is 912,904, so 1.47% of the outstanding shares have been sold short.
| Short Interest | 912,904 |
| Short Previous Month | 911,872 |
| Short % of Shares Out | 1.47% |
| Short % of Float | 1.64% |
| Short Ratio (days to cover) | 1.49 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -53.64M |
| Pretax Income | -31.08M |
| Net Income | -33.30M |
| EBITDA | -53.53M |
| EBIT | -53.64M |
| Earnings Per Share (EPS) | -$0.72 |
Full Income StatementBalance Sheet
The company has $16.43 million in cash and $474,000 in debt, giving a net cash position of $15.95 million or $0.26 per share.
| Cash & Cash Equivalents | 16.43M |
| Total Debt | 474,000 |
| Net Cash | 15.95M |
| Net Cash Per Share | $0.26 |
| Equity (Book Value) | 12.27M |
| Book Value Per Share | 0.20 |
| Working Capital | 11.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$31.11 million and capital expenditures -$4,000, giving a free cash flow of -$31.11 million.
| Operating Cash Flow | -31.11M |
| Capital Expenditures | -4,000 |
| Free Cash Flow | -31.11M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |